NABRIVA THERAPEUTICS PLC's ticker is and the CUSIP is G63637105. A total of 47 filers reported holding NABRIVA THERAPEUTICS PLC in Q3 2019. The put-call ratio across all filers is 0.62 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $750,000 | -19.6% | 1,407,893 | +1.8% | 0.02% | -26.5% |
Q2 2020 | $933,000 | +526.2% | 1,383,192 | +434.2% | 0.03% | +325.0% |
Q1 2020 | $149,000 | -57.7% | 258,916 | -2.8% | 0.01% | -50.0% |
Q4 2019 | $352,000 | -25.4% | 266,384 | +12.9% | 0.02% | -38.5% |
Q3 2019 | $472,000 | -16.2% | 235,875 | +1.8% | 0.03% | -7.1% |
Q2 2019 | $563,000 | -0.4% | 231,754 | +0.2% | 0.03% | -6.7% |
Q1 2019 | $565,000 | +59.6% | 231,373 | -4.6% | 0.03% | +20.0% |
Q4 2018 | $354,000 | -47.0% | 242,582 | -1.9% | 0.02% | -30.6% |
Q3 2018 | $668,000 | – | 247,276 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 191,028 | $462,000 | 0.08% |
Sterling Investment Advisors, Ltd. | 5,000 | $12,000 | 0.00% |
IFP Advisors, Inc | 0 | $0 | 0.00% |